Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma

Cancer Research

Volumn 64, Issue 6, 2004, Pages 2047-2053

  Hughes, Dennis P M ^a,c   Thomas, Dafydd G ^a,b   Giordano, Thomas J ^a   Baker, Laurence H ^b   McDonagh, Kevin T ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Univ of Michigan Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4;

ARTICLE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; ONCOGENE NEU; OSTEOSARCOMA; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; STAINING; WESTERN BLOTTING;

BONE NEOPLASMS; CELL MEMBRANE; CELL NUCLEUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; OSTEOSARCOMA; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 1542615081     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3096     Document Type: Article

References (62)

1. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Investig 2001;19:292-315.
2. Meyer WH, Malawer MM. Osteosarcoma. Clinical features and evolving surgical and chemotherapeutic strategies. Pediatr Clin N Am 1991;38:317-48.
3. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
4. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: an updated report. J Clin Oncol 2000;18:4016-27.
5. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2003;21:2011-8.
6. Bacci G, Ferrari S, Longhi A, et al. Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Oncol Rep 2001;8:883-8.
7. Goorin A, Andersen J. Experience with multiagent chemotherapy for osteosarcoma. Improved outcome. Clin Orthop 1991;22-8.
8. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, Adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 2000;7:339-46.
9. Yarden Y, Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 1987;26:1443-51.
10. Yarden Y, Schlessinger J. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry 1987;26:1434-42.
11. Cohen S, Ushiro H, Stoscheck C, Chinkers M. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 1982;257:1523-31.
12. Neve R, Holbro T, Hynes N. Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 2002;21:4567-76.
13. Gilmore AP, Valentijn AJ, Wang P, et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 2002;277:27643-50.
14. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC) 1987;235:177-82.
15. Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999;96:4995-5000.
16. Sweeney C, Carraway KL III. Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene 2000;19:5568-73.
17. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
18. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87.
19. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
20. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999;26:78-83.
21. Fry D. Mechanism of action of erbB tyrosine kinase inhibitors. Exp Cell Res 2003;284:131-9.
22. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-8.
23. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer (Phila.) 1996;77:71-8.
24. Morris CD, Gorlick R, Huvos G, et al. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res 2001;59-65.
25. Zhou H, Randall R, Brothman A, et al. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25:27-32.
26. Akatsuka T, Wada T, Kokai Y, et al. Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology (Basel) 2001;60:361-6.
27. Maitra A, Wanzer D, Weinberg AG, Ashfaq R. Amplification of the HER-2/ neu oncogene is uncommon in pediatric osteosarcomas. Cancer (Phila.) 2001;92:677-83.
28. Kilpatrick SE, Geisinger KR, King TS, et al. Clinicopathologic analysis of HER-2/ neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 2001;14:1277-83.
29. Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002;8:788-93.
30. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer (Phila.) 2002;94:1397-404.
31. Witlox M, Van Beusechem V, Grill J, et al. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J Gene Med 2002;4:510-6.
32. Burke P, Schooler K, Wiley HS. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 2001;12:1897-910.
33. Wiley H. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 2003;284:78-88.
34. Rio C, Buxbaum JD, Peschon JJ, Corfas G. Tumor necrosis factor-α-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 2000;275:10379-87.
35. Ni C-Y, Murphy MP, Golde TE, Carpenter G. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (Wash. DC) 2001;294:2179-81.
36. Lee H-J, Jung K-M, Huang YZ, et al. Presenilin-dependent γ-secretase-like intramembrane cleavage of ErbB4. J Biol Chem 2002;277:6318-23.
37. Srinivasan R, Gillett CE, Barnes DM, Gullick WJ. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 2000;60:1483-7.
38. Murray E, Provvedini D, Curran D, et al. Characterization of a human osteoblastic osteosarcoma cell line (SAOS-2) with high bone alkaline phosphatase activity. J Bone Miner Res 1987;2:231-8.
39. Oliner J, Kinzler K, Meltzer P, George D, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (Lond.) 1992;358:80-3.
40. Dini M, Jafari K, Faiferman I. Cell-mediated cytotoxicity in preinvasive and invasive squamous cell carcinoma of the cervix. Obstet Gynecol 1980;55:728-31.
41. Soule HD, Vazquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst (Bethesda) 1973;51:1409-16.
42. Fabricant R, De Larco J, Todaro G. Nerve growth factor receptors on human melanoma cells in culture. Proc Natl Acad Sci USA 1977;74:565-9.
43. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
44. Heid C, Stevens J, Livak K, Williams P. Real time quantitative PCR. Genome Res 1996;6:986-94.
45. Shawver L, Mann E, Elliger S, Dugger T, Arteaga C. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells. Cancer Res 1994;54:1367-73.
46. Carlin C, Knowles B. Biosynthesis of the epidermal growth factor receptor in human epidermoid carcinoma-derived A431 cells. J Biol Chem 1984;259:7902-8.
47. Jorissen R, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
48. Moriki T, Maruyama H, Maruyama I. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J Mol Biol 2001;311:1011-26.
49. Sakaguchi K, Okabayashi Y, Kido Y, et al. Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells. Mol Endocrinol 1998;12:536-43.
50. Sasaoka T, Langlois W, Leitner J, Draznin B, Olefsky J. The signaling pathway coupling epidermal growth factor receptors to activation of p21ras. J Biol Chem 1994;269:32621-5.
51. Karni R, Jove R, Levitzki A. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 1999;18:4654-62.
52. Wahl M, Nishibe S, Kim J, et al. Identification of two epidermal growth factor-sensitive tyrosine phosphorylation sites of phospholipase C-γ in intact HSC-1 cells. J Biol Chem 1990;265:3944-8.
53. Slaaby R, Jensen T, Hansen HS, Frohman MA, Seedorf K. PLD2 complexes with the EGF receptor and undergoes tyrosine phosphorylation at a single site upon agonist stimulation. J Biol Chem 1998;273:33722-7.
54. David M, Wong L, Flavell R, et al. STAT activation by epidermal growth factor (EGF) and amphiregulin. J Biol Chem 1996;271:9185-8.
55. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE. ErbB receptor-induced activation of Stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 1999;274:17209-18.
56. Wiesen J, Young P, Werb Z, Cunha G. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development (Cambr.) 1999;126:335-44.
57. Morris J, Lin W, Hauser C, et al. Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development. Neuron 1999;23:273-83.
58. Shupnik M, Antoniades H, Tashjian A. Platelet-derived growth factor increases prostaglandin production and decreases epidermal growth factor receptors in human osteosarcoma cells. Life Sci 1982;30:347-53.
59. Yamada K, Yoshitake Y, Norimatsu H, Nishikawa K. Roles of various growth factors in growth of human osteosarcoma cells which can grow in protein-free medium. Cell Struct Funct 1992;17:9-17.
60. Tong L, Yamaguchi N, Kita M, Imanishi J. Enhancement of the growth of human osteosarcoma cells by human interferon-γ. Cell Struct Funct 1992;17:257-61.
61. 2 by cultured osteosarcoma cell line. Acta Endocrinol (Copenh.) 1984;107:125-30.
62. Oda Y, Wehrmann B, Radig K, et al. Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. Gen Diagn Pathol 1995;141:97-103.